Captain T Cell, a Schoenefeld/Berlin, Germany-based biotechnology company developing T cells against solid tumors, raised €8.5M in Seed funding.
Backers included i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H. In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the company through its GO-Bio program. The financing also marks the appointment of Jörn Aldag as Chairman of the Board of Directors.
The company intends to use the funds to further progress its lead program towards the clinic along with a novel allogeneic platform for off-the-shelf treatments of solid tumors.
Led by CEO Dr. Felix Lorenz, Captain T Cell develops efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies. Using a toolbox of technologies, itl generates TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In preclinical in vivo models, the company has been able to eradicate aggressive tumors using these efficacy-enhanced T cells. A key technology established by the Captain T Cell team is its proprietary TCR-ALLO platform for off-the-shelf treatment of solid tumors, which is a versatile tool that can be expanded to a variety of cancer indications.
The company is a spin-off from the Max Delbrück Center, Berlin, Germany, a leading European biomedical research institution.
FinSMEs
22/05/2024